about
Prevalence of chronic hepatitis B virus infection in Thailand: a systematic review and meta-analysisHaematological safety of perinatal zidovudine in pregnant HIV-1-infected women in Thailand: secondary analysis of a randomized trialResistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysisSwitching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in ThailandContribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in ThailandWeight as predictors of clinical progression and treatment failure: results from the TREAT Asia Pediatric HIV Observational DatabaseEfficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapineHematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand.Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in ThailandInfluence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancyLong-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study.Early HIV-1 diagnosis using in-house real-time PCR amplification on dried blood spots for infants in remote and resource-limited settingsNo relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.Cost-effectiveness of early infant HIV diagnosis of HIV-exposed infants and immediate antiretroviral therapy in HIV-infected children under 24 months in ThailandEstimating the timing of mother-to-child transmission of the human immunodeficiency virus type 1 using a viral molecular evolution modelThe interrelated transmission of HIV-1 and cytomegalovirus during gestation and delivery in the offspring of HIV-infected mothers.Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmissionInfant outcomes after maternal antiretroviral exposure in resource-limited settings.Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function ImpairmentResistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited settingRisk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy.Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant womenFive-year trends in antiretroviral usage and drug costs in HIV-infected children in ThailandEarly postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus.Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring.Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.Hospitalization trends, costs, and risk factors in HIV-infected children on antiretroviral therapy.Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand.
P50
Q28066920-128408DA-CC43-4715-9E70-4DBAE15856EAQ28469195-4C0A6543-5A49-43A4-9966-8858E0A59B05Q28478121-076ECD35-36A9-421B-A92F-2AE34A7E1A4DQ28535141-44CAA343-BFA9-4C87-B94E-8DF078C3ECC5Q33714594-3E499501-A746-4EC6-B18D-00A3EF3EA98CQ33798282-CF11723A-D26C-4044-AFCD-D4F53254BCCBQ33827080-E2DFC454-DD44-4BE2-B60B-51987095CD2BQ33915385-3DACE552-E89A-4E13-B2D1-6656E6895588Q34051420-CDF6375E-EF64-4D78-8CCD-03876333D25BQ34071112-45FE4A24-C02B-4139-BF04-48551B110C66Q34315335-A1C27690-18E3-409E-9A47-003D5DFE6AE0Q34332659-D824DBB0-AD93-4BE4-A532-F14521E0F424Q34364620-39D25D5E-4D15-4BF1-A1EB-9C786A92834CQ34385049-B78C184E-7F8D-467D-A8A0-0A3A2BE2940DQ34677780-0119052E-92FC-4AF0-B711-1F743B5A54F2Q34710705-73543D9E-9258-4865-B3A0-53D8BC1C197FQ34758192-96015199-992E-48D2-BE0E-5C997D4CFE91Q35019846-312725F1-4156-4FBC-B7A6-61C0B9F1DDA5Q35036360-7198B63C-EA9D-4AFF-A96F-0A5939F8BDCEQ35102254-FFD28AFE-AFDC-4326-9D96-BA062EC7B7E4Q35121725-4AB85DC0-65A8-4F0C-8E31-4B5C9382ABE4Q35143626-09DAB72D-0AFB-4883-AADD-2A7640DFFD0AQ35612521-887316F7-C116-4500-91D3-9A5CCF2C9E0FQ35625548-8A8694EB-E134-4F37-BE18-1782BFDC789FQ35632898-2F1461F1-32A4-48ED-A366-226280A97CCAQ35744396-4F62BF04-E004-40B2-85E4-09C6D8736E19Q35996783-8553E1C8-DD52-4FC1-992D-9D33CB53703AQ36167503-B3AA9418-F34F-44E4-A366-2BEB40458D1CQ36201097-8E35447E-7A5E-4733-98E8-7E1067BE46EFQ36311894-F6039541-97ED-40FD-A1F6-53FF7CDD25A4Q36757599-EAE9DC40-A230-4E8A-9416-34F4FE684EE2Q36914202-F399FA1F-72A9-421E-88C5-681299F58FC1Q36999993-F0FA07A1-704B-465D-91E0-05328BF42A8CQ37098285-C240D70D-A31C-45D6-9C8C-A727A959C4B8Q37190708-BAFBCA7A-741D-4E34-9783-2206A368CED9Q37357573-DFB7A081-272C-45AE-81ED-C40AFC4ECE0AQ37412223-6A09B216-089F-442E-AB6D-1A5FEC5AB079Q37417511-E062AEF1-8196-46AD-9739-C6603F17B329Q38431314-31C217C4-F8F7-4D7F-A5DD-D7242E0991DEQ38434698-92E16365-7D2D-459E-AF33-BCBDFD3F9CD3
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gonzague Jourdain
@ast
Gonzague Jourdain
@en
Gonzague Jourdain
@es
Gonzague Jourdain
@nl
Gonzague Jourdain
@sl
type
label
Gonzague Jourdain
@ast
Gonzague Jourdain
@en
Gonzague Jourdain
@es
Gonzague Jourdain
@nl
Gonzague Jourdain
@sl
prefLabel
Gonzague Jourdain
@ast
Gonzague Jourdain
@en
Gonzague Jourdain
@es
Gonzague Jourdain
@nl
Gonzague Jourdain
@sl
P1053
F-9117-2017
P106
P21
P2798
P31
P3829
P496
0000-0002-3365-7020
P569
2000-01-01T00:00:00Z